---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098360"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:13:45.462143+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Dogwood Therapeutics posts Q4 2025 update presentation; no specific data in excerpt

## Summary
- Presentation filed as Exhibit 99.1 highlights first-in-class therapies for cancer neuropathy.
- No financial results, clinical data, or guidance changes included in the provided excerpt.
- Filed as Regulation FD disclosure; presentation may be used with investors and analysts.

## SEC filing metadata
- accession: 0001104659-25-098360
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465925098360/0001104659-25-098360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465925098360/dwtx-20251009x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098360
- JSON: https://secwatch.observer/filing/0001104659-25-098360.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.